Volume 26, Number 12—December 2020
CME ACTIVITY - Research
Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa
||Odds ratio (95% CI)
|Swaziland, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza, and Uganda||Referent|
|TB drug resistance|
|Not tested, multidrug resistance, and not detected||Referent|
|On ART >6 mos before TB treatment, on ART <6 mos before TB treatment, and on ART >8 wks after TB treatment||Referent|
|Never on ART||3.38 (0.21–20.02)||0.2168|
|On ART <8 wks after starting TB treatment
|Not advanced||0.42 (0.13–0.94)||0.0412†|
|Each increasing WHO stage||3.64 (2.50–7.17)||<0.001‡|
*Variables included were sex, COE, site of TB, TB treatment category, TB drug resistance, age at ATT initiation, days in care at COE, immune status, ART TB days, ART category, and World Health Organization stage; all elements under each variable are described in Table 2. Variables excluded were ART regimen pre-ATT initiation, and total ART drugs pre-ATT treatment. ART, antiretroviral therapy; ATT, anti-TB therapy; COE, Center of Excellence; TB, tuberculosis. †Significant result (p<0.05). ‡Significant result (p<0.01).
1These authors contributed equally to this article.